Ann-Charlotte Iversen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1305659/publications.pdf

Version: 2024-02-01

55 papers	1,826 citations	257450 24 h-index	276875 41 g-index
64 all docs	64 docs citations	64 times ranked	2860 citing authors

#	Article	IF	Citations
1	Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 39-52.	3.6	11
2	Divergent Regulation of Decidual Oxidative-Stress Response by NRF2 and KEAP1 in Preeclampsia with and without Fetal Growth Restriction. International Journal of Molecular Sciences, 2022, 23, 1966.	4.1	11
3	Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia. Frontiers in Immunology, 2022, 13, 842451.	4.8	5
4	TLR3 expression by maternal and fetal cells at the maternal-fetal interface in normal and preeclamptic pregnancies. Journal of Leukocyte Biology, 2021, 109, 173-183.	3.3	14
5	Decidual and placental NOD1 is associated with inflammation in normal and preeclamptic pregnancies. Placenta, 2021, 105, 23-31.	1.5	10
6	Systemic immunological perturbations and placental pathology in preeclampsia. Placenta, 2021, 112, e18-e19.	1.5	0
7	Cytokine Patterns in Maternal Serum From First Trimester to Term and Beyond. Frontiers in Immunology, 2021, 12, 752660.	4.8	40
8	Cholesterol Crystals and NLRP3 Mediated Inflammation in the Uterine Wall Decidua in Normal and Preeclamptic Pregnancies. Frontiers in Immunology, 2020, 11, 564712.	4.8	15
9	Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nature Communications, 2020, 11, 5976.	12.8	102
10	NLRP3 inflammasome expression by maternal and fetal cells in the decidua and its association with preeclampsia. Placenta, 2019, 83, e15.	1.5	1
11	Metabolomics Identifies Placental Dysfunction and Confirms Flt-1 (FMS-Like Tyrosine Kinase Receptor 1) Biomarker Specificity. Hypertension, 2019, 74, 1136-1143.	2.7	14
12	Hypertensive pregnancy disorders increase the risk of maternal cardiovascular disease after adjustment for cardiovascular risk factors. International Journal of Cardiology, 2019, 282, 81-87.	1.7	39
13	Serum cytokine patterns in first half of pregnancy. Cytokine, 2019, 119, 188-196.	3.2	29
14	Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity. Pregnancy Hypertension, 2019, 17, S5.	1.4	0
15	Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clinical and Experimental Immunology, 2018, 193, 84-94.	2.6	75
16	Placental inflammation by HMGB1 activation of TLR4 at the syncytium. Placenta, 2018, 72-73, 53-61.	1.5	24
17	Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617Â589 Norwegian Women. Journal of the American Heart Association, 2018, 7, .	3.7	85
18	Incident Coronary Heart Disease After Preeclampsia: Role of Reduced Fetal Growth, Preterm Delivery, and Parity. Journal of the American Heart Association, 2017, 6, .	3.7	77

#	Article	IF	Citations
19	Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nature Genetics, 2017, 49, 1255-1260.	21.4	205
20	The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. Journal of Hypertension, 2017, 35, 132-139.	0.5	15
21	NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies. Placenta, 2016, 45, 88.	1.5	0
22	Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. Journal of Hypertension, 2015, 33, 2294-2302.	0.5	21
23	Metaâ€analysis of the human leukocyte antigenâ€C (<scp>HLA</scp>â€C) 14 bp insertion/deletion polymorphism as a risk factor for preeclampsia. Tissue Antigens, 2015, 86, 186-194.	1.0	24
24	First Trimester Urine and Serum Metabolomics for Prediction of Preeclampsia and Gestational Hypertension: A Prospective Screening Study. International Journal of Molecular Sciences, 2015, 16, 21520-21538.	4.1	55
25	[278-POS]. Pregnancy Hypertension, 2015, 5, 138-139.	1.4	0
26	Distinct First Trimester Cytokine Profiles for Gestational Hypertension and Preeclampsia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2478-2485.	2.4	36
27	Toll-like receptor profiling of seven trophoblast cell lines warrants caution for translation to primary trophoblasts. Placenta, 2015, 36, 1246-1253.	1.5	30
28	Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta, 2015, 36, 1455-1462.	1.5	53
29	Metabolomic Biomarkers in Serum and Urine in Women with Preeclampsia. PLoS ONE, 2014, 9, e91923.	2.5	54
30	Functional Toll-like receptors in primary first-trimester trophoblasts. Journal of Reproductive Immunology, 2014, 106, 89-99.	1.9	45
31	Preeclampsia and cardiovascular disease share genetic risk factors on chromosome 2q22. Pregnancy Hypertension, 2014, 4, 178-185.	1.4	14
32	InterPregGen:genetic studies of pre-eclampsia in three continents. Norsk Epidemiologi, 2014, 24, 141-146.	0.3	12
33	PP042. Cell surface toll-like receptors in primary first trimester trophoblasts. Pregnancy Hypertension, 2013, 3, 81-82.	1.4	1
34	PP002. Metabolomic biomarkers in serum and urine of preeclamptic women. Pregnancy Hypertension, 2013, 3, 67-68.	1.4	0
35	OP004. A SNP associated with susceptibility to preeclampsia near the inhibin, beta B gene, is also associated with cardiovascular disease risk traits. Pregnancy Hypertension, 2013, 3, 63.	1.4	0
36	PP040. Activation of endosomal toll-like receptors in first trimester trophoblasts. Pregnancy Hypertension, 2013, 3, 81.	1.4	0

#	Article	IF	Citations
37	Inflammatory mechanisms in preeclampsia. Pregnancy Hypertension, 2013, 3, 58.	1.4	8
38	Changing patterns of cytomegalovirus seroprevalence among pregnant women in Norway between 1995 and 2009 examined in the Norwegian Mother and Child Cohort Study and two cohorts from SÃ¸r-TrÃ¸ndelag County: a cross-sectional study. BMJ Open, 2013, 3, e003066.	1.9	18
39	Mediators of the association between pre-eclampsia and cerebral palsy: population based cohort study. BMJ, The, 2013, 347, f4089-f4089.	6.0	59
40	Cytomegalovirus antibody status at 17â€“18â€ƒweeks of gestation and preâ€eclampsia: a caseâ€“control study of pregnant women in Norway. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1316-1323.	2.3	13
41	OS046. Genome-wide association scans identify novel maternalsusceptibility loci for preeclampsia. Pregnancy Hypertension, 2012, 2, 202.	1.4	2
42	OS070. Shared genetic risk factors for preeclampsia and cardiovascular disease. Pregnancy Hypertension, 2012, 2, 214-215.	1.4	0
43	Genome-Wide Association Scan Identifies a Risk Locus for Preeclampsia on 2q14, Near the Inhibin, Beta B Gene. PLoS ONE, 2012, 7, e33666.	2.5	110
44	IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients. Journal of Immunology, 2009, 182, 588-595.	0.8	27
45	A Proviral Role for CpG in Cytomegalovirus Infection. Journal of Immunology, 2009, 182, 5672-5681.	0.8	31
46	The HLA-G 14bp gene polymorphism and decidual HLA-G 14bp gene expression in pre-eclamptic and normal pregnancies. Journal of Reproductive Immunology, 2008, 78, 158-165.	1.9	52
47	Fetal growth restriction is associated with reduced FasL expression by decidual cells. Journal of Reproductive Immunology, 2007, 74, 7-14.	1.9	22
48	A comparative study of immunomagnetic methods used for separation of human natural killer cells from peripheral blood. Journal of Immunological Methods, 2005, 303, 1-10.	1.4	19
49	Human NK Cells Inhibit Cytomegalovirus Replication through a Noncytolytic Mechanism Involving Lymphotoxin-Dependent Induction of IFN-Î². Journal of Immunology, 2005, 175, 7568-7574.	0.8	37
50	The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis. Cancer Immunology, Immunotherapy, 1999, 48, 139-146.	4.2	22
51	REGULATION OF APO-2 LIGAND/TRAIL EXPRESSION IN NK CELLSâ€”INVOLVEMENT IN NK CELL-MEDIATED CYTOTOXICITY. Cytokine, 1999, 11, 664-672.	3.2	83
52	Apoptosis, proliferation and NFâ€ÎºB activation induced by agonistic Fas antibodies in the human myeloma cell line OHâ€2: amplification of Fasâ€mediated apoptosis by tumor necrosis factor. European Journal of Haematology, 1999, 63, 345-353.	2.2	21
53	REGULATION OF FAS AND FAS-LIGAND EXPRESSION IN NK CELLS BY CYTOKINES AND THE INVOLVEMENT OF FAS-LIGAND IN NK/LAK CELL-MEDIATED CYTOTOXICITY. Cytokine, 1997, 9, 394-404.	3.2	75
54	Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. European Journal of Immunology, 1995, 25, 2714-2717.	2.9	32

#	Article	IF	Citations
55	Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. European Journal of Immunology, 1993, 23, 1831-1838.	2.9	77